Most Recent
In what a judge has dubbed a “tale of two women, two teenage dreams and one name”, US pop star Katy Perry has lost her bid to cancel the “Katie Perry” trade mark owned by an Australian designer and has been barred her from using her stage name to market clothing merchandise.
German pharmaceutical giant Bayer has slammed generic drug make Sandoz’s late bid for documents, which it called an attempt to “divert and distract” Bayer on the eve of a three-week trial over the patents for its top-selling blood clot drug Xarelto.
Lawyerly's Litigation Law Firms of 2022 racked up precedent-setting victories in a year that continued to see major developments in class action law.
US tool giant Illinois Tool Works has defeated an appeal to a ruling that found Australian tool company Airco infringed it patent for a fuel cell designed for use in combustion tools.
A judge has found Shenzhen-based based radio manufacturer Hytera engaged in "substantial industrial theft" by appropriating Motorola's source code for its digital mobile radios and should be on the hook for additional damages for "flagrantly" infringing Motorola's copyright.
Gaming company Konami will cough up $35.9 million dollars to rival company Aristocrat Technologies next year, eight years after a judge found that it had violated Aristocrat’s patent for a slot machine with an improved jackpot feature.
Gaming company Konami Australia has been ordered to pay rival Aristocrat Technologies a proportion of profits from the sale of patent-infringing poker machines over a 12-year period, as well as a chunk of damages for supply of the games that generated no revenue at all.
Trial in the battle of the buns has begun, with McDonald's laying out a case for why its rival's Big Jack burger infringes its trade mark, and Hungry Jack's firing back that consumers could not confuse its flame-grilled meal with the iconic Big Mac.
Mineral exploration company Boart Longyear has been granted leave to appeal a finding that it infringed a patent for a mining tool, but it can't avoid a recall of its tools, with a judge saying its actions were “not uninformed or innocent”.
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant's patents for blockbuster MS drug Gilenya.